MA38284B1 - Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one - Google Patents

Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one

Info

Publication number
MA38284B1
MA38284B1 MA38284A MA38284A MA38284B1 MA 38284 B1 MA38284 B1 MA 38284B1 MA 38284 A MA38284 A MA 38284A MA 38284 A MA38284 A MA 38284A MA 38284 B1 MA38284 B1 MA 38284B1
Authority
MA
Morocco
Prior art keywords
dihydroimidazol
pla2
lipoprotein
pyrimidin
inhibitors
Prior art date
Application number
MA38284A
Other languages
English (en)
Other versions
MA38284A1 (fr
Inventor
Yingxia Sang
Zehong Wan
Qing Zhang
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50002724&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38284(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA38284A1 publication Critical patent/MA38284A1/fr
Publication of MA38284B1 publication Critical patent/MA38284B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne de nouveaux composés qui inhibent l'activité de la lp-pla2, des procédés pour leur préparation, des compositions les contenant et leur utilisation pour le traitement de maladies associées à l'activité de la lp-pla2, par exemple l'athérosclérose et la maladie d'alzheimer.
MA38284A 2013-01-25 2014-01-23 Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one MA38284B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013070976 2013-01-25
CN2013001556 2013-12-12
PCT/EP2014/051286 WO2014114694A1 (fr) 2013-01-25 2014-01-23 Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one

Publications (2)

Publication Number Publication Date
MA38284A1 MA38284A1 (fr) 2017-12-29
MA38284B1 true MA38284B1 (fr) 2018-05-31

Family

ID=50002724

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38284A MA38284B1 (fr) 2013-01-25 2014-01-23 Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one

Country Status (23)

Country Link
US (1) US9708330B2 (fr)
EP (1) EP2948452B1 (fr)
JP (1) JP6306053B2 (fr)
KR (1) KR20150108897A (fr)
CN (1) CN105008368B (fr)
AU (1) AU2014209949B2 (fr)
BR (1) BR112015017759B1 (fr)
CA (1) CA2899091A1 (fr)
CL (1) CL2015002060A1 (fr)
CR (1) CR20150390A (fr)
EA (1) EA025885B1 (fr)
ES (1) ES2642762T3 (fr)
HK (1) HK1216425A1 (fr)
IL (1) IL240046A0 (fr)
MA (1) MA38284B1 (fr)
MX (1) MX2015009633A (fr)
PE (1) PE20151251A1 (fr)
PH (1) PH12015501586A1 (fr)
SG (1) SG11201505520WA (fr)
TW (1) TW201443054A (fr)
UY (1) UY35276A (fr)
WO (1) WO2014114694A1 (fr)
ZA (1) ZA201505025B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948452B1 (fr) 2013-01-25 2017-08-09 GlaxoSmithKline Intellectual Property Development Limited Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
CN106536521B (zh) * 2014-07-22 2018-08-03 葛兰素史密斯克莱知识产权发展有限公司 化合物
WO2016012916A1 (fr) * 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
WO2016012917A1 (fr) * 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
CN104892459A (zh) * 2015-06-16 2015-09-09 苏州明锐医药科技有限公司 利奥西呱中间体及其制备方法
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
CN112778331B (zh) * 2019-11-09 2022-07-05 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN111533699B (zh) * 2020-05-27 2023-12-01 龙曦宁（上海）医药科技有限公司 一种2-（三氟甲基）嘧啶-5-醇的合成方法
CN113861220B (zh) * 2020-06-30 2023-06-16 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN113912622B (zh) * 2020-07-10 2023-12-01 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
CN114057740B (zh) * 2021-12-15 2024-04-02 上海赛默罗生物科技有限公司 螺环嘧啶酮衍生物、其制备方法、药物组合物和用途
EP4565587A1 (fr) * 2022-08-04 2025-06-11 4B Technologies (Beijing) Co., Limited Composés de dihydroimidazo-pyrimidinone utiles en tant qu'inhibiteurs de lp-pla2 et leur utilisation
TWI896037B (zh) 2023-07-17 2025-09-01 大陸商上海樞境生物科技有限公司 雙環[5,6]咪唑嘧啶酮類衍生物、其製備方法和應用
CN116925023B (zh) * 2023-07-18 2025-11-21 江苏桐孚高新材料有限公司 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018035A1 (fr) 1992-03-04 1993-09-16 Abbott Laboratories Antagonistes des recepteurs de l'angiotensine ii
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
CN1175246A (zh) 1994-12-22 1998-03-04 史密丝克莱恩比彻姆有限公司 用于治疗动脉粥样硬化的取代的氮杂环丁－2－酮
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
JP2002515852A (ja) 1995-07-01 2002-05-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のためのアゼチジノン誘導体
EP0859834A2 (fr) 1995-09-29 1998-08-26 Smithkline Beecham Plc Paf-acetylhydrolase paf et son utilisation en therapie
WO1997021675A1 (fr) 1995-12-08 1997-06-19 Smithkline Beecham Plc Derives de beta-lactame monocycliques utilises dans le traitement de l'atherosclerose
WO1997021676A1 (fr) 1995-12-08 1997-06-19 Smithkline Beecham Plc Composes azetidinone destines au traitement de l'atherosclerose
NZ332476A (en) 1996-04-26 2000-06-23 Smithkline Beecham Plc substituted 4-(carboxybenzylsulphinyl)-2-oxo-azetidine derivatives
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
WO1999024420A1 (fr) 1997-11-06 1999-05-20 Smithkline Beecham Plc Composes de pyrimidinone et compositions pharmaceutiques les renfermant
US6559155B1 (en) 1998-08-21 2003-05-06 Smithkline Beecham P.L.C. Pyrimidinone derivatives for the treatment of atherosclerosis
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
HUP0201122A3 (en) 1999-05-01 2003-11-28 Smithkline Beecham Plc Pyrimidinone compounds, process for their preparation and pharmaceutical compositions containing them
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
JP3757703B2 (ja) 1999-09-22 2006-03-22 凸版印刷株式会社 再封可能な開口維持部材付パウチ
EP1686119B1 (fr) 2000-02-16 2009-07-29 Smithkline Beecham Plc Dérivés de Pyrimidine-5-one comme inhibiteurs LDL-PLA2
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024807D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119795D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0119793D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127140D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127143D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127141D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208280D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
CA2530816A1 (fr) 2003-07-02 2005-01-13 Bayer Healthcare Ag 1,2,4-triazino-5(2h)-ones a substitution amide destinees au traitement de maladies inflammatoires chroniques
DE102004061009A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
DE102004061008A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one
US20080090852A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
WO2008048867A2 (fr) * 2006-10-13 2008-04-24 Glaxo Group Limited Composés hétoroaromatiques bicycliques
US7705005B2 (en) 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080090851A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
AU2008251467B2 (en) 2007-05-11 2014-07-31 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
US20080279846A1 (en) 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
JP2011088847A (ja) 2009-10-21 2011-05-06 Takeda Chem Ind Ltd 三環性化合物およびその用途
US8871928B2 (en) * 2010-09-20 2014-10-28 Glaxo Group Limited Tricyclic compounds, preparation methods, and their uses
JP2013544854A (ja) * 2010-12-06 2013-12-19 グラクソ グループ リミテッド 化合物
EP2651403B1 (fr) 2010-12-17 2020-12-02 Glaxo Group Limited Procédés de traitement et de prévention de maladies oculaires
EP2739627A4 (fr) * 2011-07-27 2015-01-21 Glaxo Group Ltd Composés 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1h)-one et utilisation en tant qu'inhibiteurs de lp-pla2
CN103827116B (zh) * 2011-07-27 2016-08-31 葛兰素集团有限公司 用作LP-PLA2抑制剂的2,3-二氢咪唑并[1,2-c]嘧啶-5(1H)-酮化合物
EP2948452B1 (fr) 2013-01-25 2017-08-09 GlaxoSmithKline Intellectual Property Development Limited Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one

Also Published As

Publication number Publication date
BR112015017759B1 (pt) 2022-05-24
EP2948452A1 (fr) 2015-12-02
JP2016505058A (ja) 2016-02-18
PH12015501586A1 (en) 2015-10-05
CN105008368A (zh) 2015-10-28
IL240046A0 (en) 2015-08-31
WO2014114694A1 (fr) 2014-07-31
TW201443054A (zh) 2014-11-16
MX2015009633A (es) 2015-11-30
US9708330B2 (en) 2017-07-18
EA025885B1 (ru) 2017-02-28
EP2948452B1 (fr) 2017-08-09
ZA201505025B (en) 2017-08-30
AU2014209949B2 (en) 2016-09-08
PE20151251A1 (es) 2015-09-10
EA201591379A1 (ru) 2016-01-29
MA38284A1 (fr) 2017-12-29
BR112015017759A2 (pt) 2017-07-11
HK1216425A1 (zh) 2016-11-11
SG11201505520WA (en) 2015-08-28
CA2899091A1 (fr) 2014-07-31
KR20150108897A (ko) 2015-09-30
JP6306053B2 (ja) 2018-04-04
CL2015002060A1 (es) 2015-11-27
UY35276A (es) 2014-08-29
CR20150390A (es) 2015-10-19
CN105008368B (zh) 2017-02-01
US20150361082A1 (en) 2015-12-17
AU2014209949A1 (en) 2015-07-30
ES2642762T3 (es) 2017-11-20

Similar Documents

Publication Publication Date Title
MA38284A1 (fr) Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
MA39219A1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
EA202091709A1 (ru) Ингибиторы днк-пк
EA202091708A1 (ru) Ингибиторы днк-пк
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
MA49809A1 (fr) Composés utilisés comme inhibiteurs de kinase
MA44948A1 (fr) Inhibiteurs de bace 1
TN2009000551A1 (fr) Nouveaux composes chimiques
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MA38483A1 (fr) Inhibiteurs de l'ido
MA38986A3 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines
MA39145B1 (fr) Dérivés de pipérazine ayant une activité multimode contre la douleur
MA38327A2 (fr) Dihydropyrimidinones bicycliques substituées et leur utilisation à titre d'inhibiteurs de l'activité élastase neutrophile
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA41494A (fr) Composés benzoxaborole substitués en position 4 et utilisations associées
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA38925A1 (fr) Dérivés de phénylalanine substitués
MA43250B1 (fr) Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA45367B1 (fr) Inhibiteurs de la tyrosine kinase
MA44025A1 (fr) Inhibiteurs de pde9 pour le traitement de maladies périphériques
MA39260A1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c
MA38473B1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c